Novocure Ltd. (NVCR): Price and Financial Metrics
NVCR Price/Volume Stats
| Current price | $12.09 | 52-week high | $83.60 |
| Prev. close | $12.05 | 52-week low | $10.87 |
| Day low | $11.89 | Volume | 850,446 |
| Day high | $12.32 | Avg. volume | 1,361,122 |
| 50-day MA | $14.74 | Dividend yield | N/A |
| 200-day MA | $18.39 | Market Cap | 1.30B |
NVCR Stock Price Chart Interactive Chart >
Novocure Ltd. (NVCR) Company Bio
NovoCure Limited is a commercial stage oncology company which develops treatment for solid tumor cancers therapy called the tumor treating fields. The company was founded in 2000 and is based in Saint Helier, Channel Islands.
Latest NVCR News From Around the Web
Below are the latest news stories about NOVOCURE LTD that investors may wish to consider to help them evaluate NVCR as an investment opportunity.
Novocure to Participate in 42nd Annual J.P. Morgan Healthcare ConferenceROOT, Switzerland, December 27, 2023--Novocure (NASDAQ: NVCR) announced today that management will participate in the 42nd Annual J.P. Morgan Healthcare Conference on January 9-10, 2024. William Doyle, Novocure’s Executive Chairman, will speak on behalf of the company and address questions from analysts at 7:30 a.m. PST on Wednesday, January 10, 2024. Mr. Doyle and Ashley Cordova, Novocure’s Chief Financial Officer, will participate in one-on-one meetings with investors throughout the event. |
7 Nasdaq Stocks Down 59% Set to Soar at Least 141%Wall Street loves a good comeback story. |
15 Best Falling Stocks To Buy NowIn this piece, we will take a look at the 15 best falling stocks to buy now. If you want to skip our overview of the current stock market environment and our coverage of the latest stock market news, then you can skip ahead to 5 Best Falling Stocks To Buy Now. With 2023 coming […] |
The Top and Bottom Stocks of 2023Top performing stocks in 2023 included those in the technology sector, taking advantage of developments in AI. The bottom performers included NVCR, which was punished because of its ovarian cancer trials' failure to improve survival rates in patients. |
Evercore ISI Is Pounding the Table on Rivian (RIVN) Stock With Outperform RatingRivian stock is getting a boost on Tuesday after analysts at Evercore ISI weighed in on RIVN shares with a reiterated outperform rating. |
NVCR Price Returns
| 1-mo | -11.30% |
| 3-mo | -13.52% |
| 6-mo | -16.96% |
| 1-year | -80.45% |
| 3-year | -93.79% |
| 5-year | -71.36% |
| YTD | -19.02% |
| 2023 | -79.65% |
| 2022 | -2.30% |
| 2021 | -56.61% |
| 2020 | 105.34% |
| 2019 | 151.70% |
Continue Researching NVCR
Want to do more research on NovoCure Ltd's stock and its price? Try the links below:NovoCure Ltd (NVCR) Stock Price | Nasdaq
NovoCure Ltd (NVCR) Stock Quote, History and News - Yahoo Finance
NovoCure Ltd (NVCR) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...